MedPath
FDA Approval

Amikacin Sulfate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 7, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Amikacin(250 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc.

946499746

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Amikacin Sulfate

Product Details

NDC Product Code
0641-6166
Application Number
ANDA063315
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
April 7, 2023
SODIUM CITRATEInactive
Code: 1Q73Q2JULRClass: IACT
AmikacinActive
Code: N6M33094FDClass: ACTIMQuantity: 250 mg in 1 mL
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
SODIUM METABISULFITEInactive
Code: 4VON5FNS3CClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT

Amikacin Sulfate

Product Details

NDC Product Code
0641-6167
Application Number
ANDA063315
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
April 7, 2023
AmikacinActive
Code: N6M33094FDClass: ACTIMQuantity: 250 mg in 1 mL
SODIUM METABISULFITEInactive
Code: 4VON5FNS3CClass: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM CITRATEInactive
Code: 1Q73Q2JULRClass: IACT
© Copyright 2025. All Rights Reserved by MedPath